{"gene":"APOB","run_date":"2026-06-09T22:02:43","timeline":{"discoveries":[{"year":1986,"finding":"ApoB-100 is a single protein of 4560 amino acids (513 kDa) encoded by a single gene; structural analysis predicted amphipathic alpha-helices and beta-sheets as lipid-binding domains, and identified a region (residues 3352-3369) with sequence homology to the LDL receptor-binding site of apoE, flanked by positively charged regions (3174-3681) proposed as the LDL receptor-binding domain.","method":"Full-length cDNA sequencing, S1 nuclease mapping of transcription start site, computer secondary structure analysis","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1 / Strong — complete primary structure determination by recombinant DNA methods, replicated across labs and foundational to the field","pmids":["3030729"],"is_preprint":false},{"year":1992,"finding":"ApoB-100 is cotranslationally integrated into lipoproteins during translocation into the ER lumen; nascent apoB polypeptides are released from ribosomes (via puromycin) and found on lipoprotein particles whose density is inversely related to polypeptide length, establishing that lipoprotein assembly begins co-translationally.","method":"Pulse-chase with puromycin/cycloheximide treatment, sucrose gradient ultracentrifugation, electron microscopy, transfection of truncated apoB minigenes, sodium carbonate extraction","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple orthogonal methods (puromycin release, gradient fractionation, EM, minigene transfection) in a single rigorous study","pmids":["1315773"],"is_preprint":false},{"year":2003,"finding":"MTP binds apoB with high affinity at multiple sites within the N-terminal betaalpha1 structural domain of apoB; this binding is mediated by ionic interactions, is modulated by lipids (lipids on MTP increase binding while lipids on apoB decrease it), and is functionally important for apoB secretion as demonstrated by site-directed mutagenesis, deletion analyses, and a specific antagonist (AGI-S17) that inhibits apoB-MTP binding without affecting MTP lipid transfer activity.","method":"Co-immunoprecipitation, site-directed mutagenesis, deletion analysis, antagonist (AGI-S17) inhibition, lipid modulation experiments","journal":"Journal of lipid research","confidence":"High","confidence_rationale":"Tier 1 / Strong — mutagenesis, reconstituted binding assays, specific antagonist, multiple orthogonal approaches across multiple publications","pmids":["12518019","10769147"],"is_preprint":false},{"year":1997,"finding":"ApoB-100 undergoes post-translational degradation via two distinct pathways: (1) a cytosolic/proteasome-dependent pathway (ALLN-sensitive) that degrades partially translocated apoB at the cytosolic face of the ER membrane, and (2) an ER luminal pathway (ALLN-resistant, DTT-sensitive) that degrades fully translocated apoB; oleate facilitates translocation of apoB into the lumen, exposing it to the second pathway.","method":"Brefeldin A block of ER-to-Golgi transport, ALLN inhibition, DTT reduction, pulse-chase metabolic labeling, inhibitor combination studies in HepG2 cells","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — rigorous pharmacological dissection using multiple specific inhibitors with consistent results, single lab but multiple orthogonal approaches","pmids":["9111073"],"is_preprint":false},{"year":2003,"finding":"Blocking MTP function (by Cre-mediated gene disruption or chemical inhibition) prevents apoB-100 secretion and causes rapid degradation of apoB without its accumulation in ER microsomes; MTP inhibition does not induce ER stress markers (GRP78, GRP94, HSPs), indicating the liver degrades secretion-incompetent apoB rapidly.","method":"Cre-mediated MTP gene knockout, chemical MTP inhibitor, plasma lipid measurements, Western blot of apoB in microsomes and chaperones, mouse studies","journal":"Journal of lipid research","confidence":"High","confidence_rationale":"Tier 2 / Strong — two independent methods (genetic KO and chemical inhibition) with consistent results, in vivo mouse model","pmids":["12588952"],"is_preprint":false},{"year":2003,"finding":"A naturally occurring nontruncating APOB mutation R463W causes familial hypobetalipoproteinemia by retaining apoB in the ER and reducing secretion efficiency by ~45%; the positive charge at position 463 is critical (Ala substitution reduces secretion; Lys substitution has no effect); the R463W mutant shows increased binding to MTP compared to wild-type, implicating this local domain in apoB-MTP interaction and lipoprotein assembly.","method":"Transfection of McA-RH7777 cells with recombinant apoB constructs, pulse-chase analysis, site-directed mutagenesis (Ala, Lys, Glu, Asp substitutions), co-transfection/binding assays with MTP, molecular modeling","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — site-directed mutagenesis with functional secretion assays and MTP binding in a single rigorous study","pmids":["12551903"],"is_preprint":false},{"year":2012,"finding":"After lipidation in the ER lumen, apoB-100 can be dislocated to the cytoplasmic surface of lipid droplets (LDs) where it accumulates as ubiquitinated ApoB for proteasomal degradation; Derlin-1 mediates the pre-dislocation step (its abrogation causes lipidated apoB to accumulate in ER lumen without increasing ubiquitinated apoB on LDs), while UBXD8 (localized to LDs) mediates the post-dislocation step by recruiting p97 to LDs.","method":"siRNA knockdown of UBXD8 and Derlin-1 in Huh7 cells, immunoprecipitation, colocalization studies, ubiquitination assays, p97 recruitment assays","journal":"Molecular biology of the cell","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal knockdowns with distinct phenotypes distinguishing pre- and post-dislocation steps, co-IP for binding, multiple orthogonal methods","pmids":["22238364"],"is_preprint":false},{"year":2011,"finding":"The E3 ubiquitin ligase gp78 ubiquitinates apoB-100, committing it to p97-mediated retrotranslocation and ERAD; siRNA knockdown of gp78 reduces apoB-100 ubiquitination and cytosolic apoB-ubiquitin conjugates, increases apoB-100 secretion, and unexpectedly enhances VLDL assembly. If p97 is knocked down simultaneously with gp78, cellular apoB returns toward baseline, confirming that ubiquitination precedes p97-mediated retrotranslocation.","method":"siRNA knockdown of gp78 and p97 in HepG2 cells, radiolabeling pulse-chase, ubiquitination assays, density gradient fractionation of secreted lipoproteins","journal":"Journal of lipid research","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genetic epistasis by double KD, biochemical ubiquitination assay, metabolic labeling in a single rigorous study","pmids":["21421992"],"is_preprint":false},{"year":2020,"finding":"TM6SF2 forms a complex with ERLIN1/2 and APOB in the ER; TM6SF2 binds and stabilizes APOB via two luminal loops; ERLINs stabilize TM6SF2 (and thereby indirectly stabilize APOB, without directly binding APOB); the NAFLD-associated E167K mutation destabilizes TM6SF2, reducing APOB protein levels; knockout of Tm6sf2 or knockdown of Erlins in mice decreases hepatic APOB protein and causes hepatic lipid accumulation.","method":"Tandem affinity purification coupled to mass spectrometry, co-immunoprecipitation, domain mapping (TM6SF2 luminal loop mutants), mouse Tm6sf2 knockout and Erlins knockdown, Western blot for APOB","journal":"PLoS genetics","confidence":"High","confidence_rationale":"Tier 1 / Moderate — TAP-MS for complex identification, Co-IP for validation, domain mutagenesis, in vivo KO/KD with lipid phenotype, multiple orthogonal methods in single study","pmids":["32776921"],"is_preprint":false},{"year":2022,"finding":"The E3 ubiquitin ligase MDM2 promotes proteasomal degradation of ApoB through direct protein-protein interaction; hepatocyte-specific deletion of MDM2 increases TG-VLDL secretion and protects against diet-induced hepatic steatosis; pharmacological blockage of the MDM2-ApoB interaction alleviates hepatic steatohepatitis and fibrosis; the effect of MDM2 on VLDL metabolism is p53-independent.","method":"Hepatocyte-specific MDM2 knockout mice, co-immunoprecipitation, pharmacological MDM2-ApoB interaction inhibitor, pulse-chase/ubiquitination assays, high-fat diet model","journal":"Advanced science","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genetic KO with phenotype, direct protein interaction by Co-IP, pharmacological inhibition, p53-independence shown, multiple orthogonal methods","pmids":["35524581"],"is_preprint":false},{"year":2016,"finding":"The RNA-binding protein vigilin binds CU-rich regions in the Apob mRNA coding sequence and controls VLDL secretion by modulating ApoB translation; hepatic vigilin knockdown decreases VLDL/LDL levels and atherosclerotic plaque formation in Ldlr-/- mice.","method":"Crosslinking-based RNA-binding studies, in vivo vigilin knockdown (siRNA), VLDL/LDL quantification, atherosclerosis scoring in Ldlr-/- mice, genomic approaches","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Moderate — direct RNA-binding crosslinking, in vivo knockdown with lipid and atherosclerosis phenotype, multiple orthogonal methods","pmids":["27665711"],"is_preprint":false},{"year":2001,"finding":"LPS-binding protein (LBP) circulates in association with LDL and VLDL, and apoB accounts at least in part for LBP's interaction with these lipoproteins; LBP association with LDL/VLDL strongly enhances their capacity to bind LPS, providing a mechanism for lipoprotein-mediated LPS scavenging.","method":"Immunoprecipitation/affinity studies with purified LBP and apoB, in vitro LPS binding assays, serum fractionation from healthy persons and septic patients","journal":"The Journal of clinical investigation","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — single Co-IP/binding assay identifying apoB as LBP interaction partner, validated in both healthy and septic serum","pmids":["11160139"],"is_preprint":false},{"year":1990,"finding":"A 60-kDa transcriptional activator protein NF-BA1 binds the apoB promoter region (-79 to -63) and is essential for transcriptional activation of the apoB gene in hepatic and intestinal cells; purified NF-BA1 stimulates apoB transcription in in vitro complementation experiments and also binds regulatory regions of apoCIII, apoAII, and apoAI genes.","method":"Protein purification (Q-Sepharose, Bio-Rex 70, DNA affinity chromatography), in vitro transcription complementation, footprinting analysis, photoaffinity cross-linking","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — protein purified to homogeneity, functional in vitro transcription reconstitution, DNA footprinting; single lab but multiple rigorous biochemical methods","pmids":["2254327"],"is_preprint":false},{"year":1992,"finding":"Growth hormone (GH) regulates apoB mRNA editing in rat liver: hypophysectomy reduces the proportion of edited apoB mRNA (and thus apoB-48) from ~62% to ~29%, while GH replacement restores it to normal levels; GH regulates both editing of apoB mRNA and the proportion of apoB-48 synthesized and secreted.","method":"Hypophysectomy with hormone replacement (GH, T4, cortisol) in vivo, S1 nuclease/sequencing for mRNA editing measurement, metabolic labeling of hepatocytes, in vivo labeling experiments","journal":"Endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo genetic/hormonal manipulation with multiple outcome measures, but mechanism downstream of GH not elucidated","pmids":["1597147"],"is_preprint":false},{"year":2010,"finding":"p53 transcriptionally regulates apoB expression: p53 response elements were identified in the apoB and apobec1 genes; ChIP confirmed p53 binding; in vivo adriamycin (p53 inducer) treatment increased intestinal/liver apoB mRNA; irradiated wild-type but not p53-knockout mice showed elevated hepatic and intestinal apoB mRNA, establishing p53 as a direct transcriptional regulator of apoB.","method":"Luciferase reporter assays, chromatin immunoprecipitation (ChIP), RT-PCR in cancer cell lines, adriamycin and irradiation of C57bl/6 and p53-/- mice","journal":"Cell cycle","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP confirming direct p53 binding, functional reporter assays, p53-KO genetic control; single lab","pmids":["20890106"],"is_preprint":false},{"year":2006,"finding":"ApoB mRNA editing is regulated by a coordinated modulation of multiple editing complex components: inhibitory components CUGBP2, GRY-RBP, and hnRNP-C1 suppress editing, while apobec-1 and ACF promote it; siRNA knockdown of CUGBP2, GRY-RBP, or hnRNP-C1 in Caco-2 cells increased editing, confirming their inhibitory function.","method":"siRNA knockdown of editing components in Caco-2 cells, quantitative RT-PCR for editing levels and component expression, developmental time-course in mouse fetal intestine","journal":"American journal of physiology. Gastrointestinal and liver physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional siRNA knockdown with editing readout, developmental correlation, single lab but multiple editing components tested","pmids":["16920700"],"is_preprint":false},{"year":1998,"finding":"Hepatic lipase (HL) binds directly to apoB (including apoB-26, apoB-48, and apoB-100) but not to apoE or apoA-I, as shown by ligand blot and plate-binding assays; this HL-apoB interaction facilitates cellular uptake of LDL, as HL-enhanced LDL binding and uptake are significantly inhibited by anti-apoB monoclonal antibodies; the interaction differs from LPL in that both amino- and carboxyl-terminal apoB antibodies block HL binding equally.","method":"Ligand blot (HL binding to apoB), LDL-coated plate binding assay, 125I-LDL uptake in cell culture, anti-apoB monoclonal antibody inhibition, heparin-agarose binding assay with Kd determination","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct binding assays with purified proteins, functional cell uptake inhibition by antibodies, multiple assay formats","pmids":["9685400"],"is_preprint":false},{"year":2011,"finding":"Human resistin stimulates hepatic ApoB secretion up to 10-fold by increasing MTP activity and by reducing expression/phosphorylation of insulin signaling pathway proteins (IRS-2, Akt, ERK), thereby stabilizing ApoB; resistin also increases hepatocyte lipid content via SREBP1/SREBP2-dependent de novo lipogenesis; antibody immunoprecipitation removal of serum resistin from obese human serum reduces ApoB secretion.","method":"Human hepatocyte treatment with resistin, MTP activity assays, Western blot of insulin signaling proteins, SREBP pathway analysis, antibody immunoprecipitation of serum resistin, apoB secretion assays","journal":"Circulation research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple pathway measurements in human hepatocytes, serum depletion experiment as functional validation, single lab","pmids":["21293001"],"is_preprint":false},{"year":2001,"finding":"Naringenin and hesperetin decrease apoB secretion from HepG2 cells by (1) reducing ACAT1 and ACAT2 activities, (2) selectively decreasing ACAT2 mRNA expression, and (3) reducing MTP activity and expression; these effects reduce lipid availability for apoB-containing lipoprotein assembly.","method":"HepG2 cell apoB secretion assay, cholesterol esterification assay, ACAT1/ACAT2-transfected CHO cells (isoform selectivity), RT-PCR for ACAT2 mRNA, MTP activity assay, 125I-LDL uptake","journal":"Journal of lipid research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple mechanistic targets investigated with distinct assays, isoform-selective ACAT cells; single lab","pmids":["11352979"],"is_preprint":false},{"year":2012,"finding":"ApoB negatively regulates angiogenesis by downregulating VEGFR1 (which acts as a decoy receptor for VEGF); genetic screen identified MTP mutation in zebrafish causing vascular defects, which was rescued by manipulating apoB levels; it is the ApoB protein particle (not lipid moieties) that mediates this effect on VEGFR1 and angiogenesis, and VEGFR1 downregulation was also observed in hyperlipidemic mice.","method":"Zebrafish forward genetic screen (mtp mutant), zebrafish lipoprotein concentration manipulation, zebrafish and mouse VEGFR1 expression analysis, particle vs. lipid dissection experiments","journal":"Nature medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic screen plus functional rescue, vertebrate model validation, single lab but multiple species/approaches","pmids":["22581286"],"is_preprint":false},{"year":1999,"finding":"Myeloperoxidase (MPO) selectively oxidizes apoB-100 in LDL via HOCl generation; oxidation with MPO-H2O2-chloride system produces DNPH-reactive carbonyl modifications in specific apoB-100 tryptic peptides (including residues 53-66), with cysteinyl azo and methionine sulfoxide modifications identified; the modifications differ from those produced by reagent HOCl, suggesting direct LDL-MPO interaction at the enzyme active site.","method":"In vitro LDL oxidation with MPO, DNPH derivatization, tryptic peptide isolation by HPLC, mass spectrometric peptide characterization","journal":"Journal of lipid research","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro biochemical reconstitution with MS-based product identification, selective modification mapping on apoB-100","pmids":["10191293"],"is_preprint":false},{"year":1994,"finding":"ApoB-100 primary structure analysis identified 16 of 25 cysteine residues in disulfide form (all 14 N-terminal cysteines are disulfide-linked); two free sulfhydryl groups are at positions Cys3734 and Cys4190; trypsin susceptibility defines five structural domains; apoB-100 appears elongated and wraps around the LDL particle, with Cys3734 proposed as the cysteine linked to apo(a) in Lp(a).","method":"HPLC-based sulfhydryl/disulfide mapping, fluorescent sulfhydryl probe (iodoacetoamidofluorescein), trypsin domain mapping, protein sequencing combined with recombinant DNA","journal":"Chemistry and physics of lipids","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — direct biochemical characterization of disulfide bonds by HPLC and fluorescent probe; single lab comprehensive structural analysis","pmids":["8187250"],"is_preprint":false},{"year":2022,"finding":"Apo(a) and apoB form noncovalent intracellular complexes within hepatocytes in the ER, trans-Golgi, and early endosomes (not lysosomes); this noncovalent interaction (mediated by apo(a) LBS7,8 sites) is required for apo(a) secretion; PCSK9 enhances apo(a) secretion in an interaction-dependent manner; lomitapide reduces apo(a) secretion dependently on the noncovalent interaction; apoB siRNA knockdown reduces apo(a) secretion.","method":"Co-immunoprecipitation, coimmunofluorescence, proximity ligation assay, pulse-chase metabolic labeling, apo(a) LBS7,8 deletion mutant, PCSK9 and lomitapide treatment, siRNA knockdown of APOB","journal":"Arteriosclerosis, thrombosis, and vascular biology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — three independent methods confirming intracellular interaction (Co-IP, colocalization, PLA), functional genetic and pharmacological validation, single lab but highly rigorous","pmids":["35045727"],"is_preprint":false},{"year":2015,"finding":"Mutations in RAD21 that disrupt its transcriptional repressor function cause overexpression of APOB48 in patients with chronic intestinal pseudo-obstruction; wild-type RAD21 protein binds the APOB promoter and represses APOB expression in HEK293 cells, but the p.622 Ala>Thr mutant RAD21 fails to bind the APOB promoter.","method":"Mobility shift assay (APOB promoter binding), HEK293 cell transfection with wild-type vs. mutant RAD21, RT-PCR for APOB expression, serum APOB48 measurements in patients","journal":"Gastroenterology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct promoter binding assay, functional cell transfection, human patient correlation; single lab","pmids":["25575569"],"is_preprint":false},{"year":2014,"finding":"The LDLR repeat LR5 binds apoB-100 at two sites (site A and site B) and apoE at its receptor-binding region, at the hydrophilic convex face of LR5; these complexes are weakened at low Ca2+ and low pH, supporting a mechanism where endosomal conditions (low pH, low Ca2+) promote ligand dissociation from LDLR independent of beta-propeller displacement.","method":"NMR spectroscopy, surface plasmon resonance (SPR) with synthetic apoB peptides and LR5, pH and Ca2+ titration","journal":"The FEBS journal","confidence":"High","confidence_rationale":"Tier 1 / Moderate — NMR structure of peptide-LR5 complex with functional SPR validation, mechanistic dissection of pH/Ca2+ effects; single lab but two orthogonal structural/biophysical methods","pmids":["24447298"],"is_preprint":false},{"year":2011,"finding":"ApoB-100-containing lipoproteins are the major carriers of 3-iodothyronamine (T1AM) in human serum; apoB-100 was identified as the T1AM-binding protein by T1AM-affinity chromatography and sequence analysis; T1AM binds apoB-100-containing LDL particles with Kd ~17 nM and 1:1 stoichiometry; the binding site is highly selective for T1AM; apoB-100-containing particles enhance intracellular T1AM uptake.","method":"T1AM-affinity chromatography, protein sequence analysis, competitive binding assays with Kd determination, intracellular uptake assays, in vivo multidose T1AM treatment","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — affinity purification identifies binding partner, quantitative binding characterization, functional uptake assay; single lab","pmids":["22128163"],"is_preprint":false},{"year":2001,"finding":"ApoB-100 secondary structure (alpha-helical content) is markedly decreased and its conformation is severely altered in electronegative LDL(-), as measured by circular dichroism; tryptophan fluorescence lifetime data indicate that oxidative modification causes apoB-100 to sink into the hydrophobic lipid core of LDL(-), possibly accounting for its reduced LDL receptor binding properties.","method":"Circular dichroism spectropolarimetry, tryptophan fluorescence lifetime measurements, Laurdan generalized polarization for lipid packing","journal":"Free radical biology & medicine","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — direct biophysical structural measurements on native and oxidized LDL fractions, two spectroscopic methods; single lab","pmids":["11425493"],"is_preprint":false},{"year":2011,"finding":"HBV infection inhibits apoB production by suppressing MTP expression; HepG2.2.15 cells (HBV-expressing) show reduced apoB mRNA and protein vs. HepG2; HBV genomic clone transfection dose-dependently reduces MTP mRNA and protein, which in turn reduces apoB expression.","method":"RT-PCR and Western blot in HepG2 vs. HepG2.2.15 cells, transfection of HBV infectious clone pHBV1.3, dose-response analysis of MTP suppression","journal":"Lipids in health and disease","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, single methods (RT-PCR/Western blot), mechanism is indirect (through MTP), no reconstitution or direct binding data","pmids":["22074108"],"is_preprint":false},{"year":1985,"finding":"The human APOB-100 gene was localized to the p23-pter region of chromosome 2 by filter hybridization with apoB-100 cDNA probes and human-mouse somatic cell hybrids containing chromosome 2 translocations.","method":"Southern blot hybridization of human-mouse somatic cell hybrids containing chromosome 2 translocations with radiolabeled apoB-100 cDNA probes","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct chromosomal mapping by somatic cell hybrid hybridization; foundational genomic localization","pmids":["3840371"],"is_preprint":false},{"year":1990,"finding":"The delipidated apoB-apo(a) complex from Lp(a) is freely water-soluble at pH>6.4 (unlike delipidated apoB alone); apoB-apo(a) has amphipathic properties with apo(a) providing hydrophilic capacity and apoB providing hydrophobic lipid-binding interactions; the complex has avidity for triglyceride-rich lipoprotein particles, demonstrating that apoB's lipid-binding hydrophobic domains are accessible when freed from lipids.","method":"Delipidation of Lp(a), solubility assays, sandwich ELISA with apo(a)- and apoB-specific antibodies, interaction with Intralipid emulsion, lipoprotein binding experiments","journal":"Journal of lipid research","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — biochemical characterization of delipidated complex by multiple binding and solubility assays; single lab","pmids":["2143212"],"is_preprint":false}],"current_model":"ApoB-100 is a 4536-amino acid structural protein that is cotranslationally integrated into nascent lipoprotein particles in the ER lumen, a process dependent on its direct binding to MTP (at the N-terminal betaalpha1 domain, via ionic interactions) and on MTP's lipid transfer activity; poorly lipidated ApoB is degraded via a cytosolic/proteasome pathway (ALLN-sensitive, requiring ERAD machinery including gp78-mediated ubiquitination committing it to p97-mediated retrotranslocation) or an ER luminal pathway (DTT-sensitive), while lipidated ApoB can be dislocated to lipid droplet surfaces for proteasomal degradation via Derlin-1/UBXD8; ApoB stability is further regulated by the TM6SF2-ERLIN complex, by MDM2-mediated ubiquitination, and by vigilin-dependent translational control; ApoB-100 serves as the sole LDL receptor ligand (via its receptor-binding domain around residues 3500) and as a carrier of T1AM and LPS-binding protein; apo(a) forms noncovalent intracellular complexes with ApoB within the ER and Golgi, coupling their secretion; ApoB is transcriptionally regulated by NF-BA1 and p53, and its mRNA editing to generate ApoB-48 is controlled by a multiprotein complex whose activity is modulated by GH and coordinated inhibitory (CUGBP2, GRY-RBP, hnRNP-C1) and activating (apobec-1, ACF) components."},"narrative":{"mechanistic_narrative":"ApoB-100 is the principal structural protein of atherogenic lipoproteins, serving as a single non-exchangeable scaffold (4536 residues encoded by one gene on chromosome 2) onto which triglyceride- and cholesterol-rich particles are assembled and around which a mature particle is wrapped [PMID:3030729, PMID:8187250, PMID:3840371]. Lipoprotein assembly is co-translational: nascent ApoB is progressively lipidated during translocation into the ER lumen, producing particles whose density falls as polypeptide length increases [PMID:1315773]. This lipidation requires direct, ionic binding of ApoB's N-terminal betaalpha1 domain to MTP, an interaction modulated by lipid and separable from MTP's lipid-transfer activity; loss of MTP function or local charge mutations such as R463W traps ApoB in the ER and drives its degradation rather than secretion, the latter causing familial hypobetalipoproteinemia [PMID:12518019, PMID:10769147, PMID:12588952, PMID:12551903]. ApoB that fails to acquire lipid is eliminated through tightly regulated quality-control routes: a cytosolic proteasomal pathway acting on incompletely translocated chains and a DTT-sensitive ER-luminal pathway acting on fully translocated chains [PMID:9111073], with gp78-mediated ubiquitination committing ApoB to p97-driven retrotranslocation/ERAD, and Derlin-1/UBXD8 routing lipidated ApoB to the lipid-droplet surface for proteasomal degradation [PMID:22238364, PMID:21421992]. ApoB stability and output are further set by an ER TM6SF2-ERLIN1/2 complex that binds and stabilizes ApoB, by MDM2-mediated (p53-independent) degradation, and by vigilin-dependent translational control, linking these regulators to VLDL secretion, hepatic steatosis, and atherosclerosis [PMID:32776921, PMID:35524581, PMID:27665711]. Once secreted, ApoB-100 is the sole protein ligand for the LDL receptor, engaging LDLR repeat LR5 at defined sites in a Ca2+/pH-sensitive manner that underlies endosomal ligand release [PMID:24447298]. ApoB transcription is controlled by NF-BA1 and by p53, and intestinal generation of ApoB-48 arises from C-to-U mRNA editing by an apobec-1/ACF complex antagonized by CUGBP2, GRY-RBP, and hnRNP-C1 and modulated hormonally [PMID:2254327, PMID:20890106, PMID:16920700, PMID:1597147]. Beyond its structural and receptor roles, ApoB couples apo(a) secretion through noncovalent intracellular complexes [PMID:35045727] and serves as a carrier protein for circulating ligands.","teleology":[{"year":1986,"claim":"Establishing that ApoB-100 is a single large protein from one gene with amphipathic lipid-binding helices and an apoE-like LDL-receptor-binding region defined the molecule as the structural scaffold and receptor ligand of LDL.","evidence":"Full-length cDNA sequencing and secondary structure prediction, with chromosomal mapping to 2p23-pter by somatic cell hybrids","pmids":["3030729","3840371"],"confidence":"High","gaps":["Receptor-binding domain inferred from sequence homology, not direct binding","No experimental tertiary structure"]},{"year":1992,"claim":"Showing that ApoB is lipidated co-translationally during ER translocation answered whether particle assembly is post-translational, establishing the co-translational assembly model.","evidence":"Puromycin/cycloheximide pulse-chase, gradient fractionation, EM, and truncated minigene transfection","pmids":["1315773"],"confidence":"High","gaps":["Did not identify the lipid-transfer machinery responsible","Mechanism coupling length to density not resolved"]},{"year":1994,"claim":"Disulfide and domain mapping defined ApoB-100 as an elongated, five-domain protein wrapping the LDL particle and nominated Cys3734 as the apo(a) linkage site, framing its architecture and Lp(a) connection.","evidence":"HPLC sulfhydryl/disulfide mapping, fluorescent probe, and trypsin domain mapping","pmids":["8187250"],"confidence":"Medium","gaps":["No high-resolution structure","apo(a) linkage to Cys3734 proposed but not directly demonstrated here"]},{"year":1997,"claim":"Resolving ApoB into two degradation routes — cytosolic/proteasomal versus ER-luminal — explained how cells dispose of secretion-incompetent ApoB and linked lipid supply (oleate) to its fate.","evidence":"Pharmacological dissection (BFA, ALLN, DTT) with pulse-chase in HepG2 cells","pmids":["9111073"],"confidence":"High","gaps":["E3 ligases and luminal proteases not identified","Single cell line"]},{"year":2003,"claim":"Mapping high-affinity ApoB-MTP binding to the betaalpha1 domain via ionic interactions, and showing MTP loss causes rapid ApoB degradation without ER stress, defined MTP as the obligate assembly partner separable from lipid transfer.","evidence":"Co-IP, mutagenesis, AGI-S17 antagonist, plus Cre MTP knockout and chemical inhibition in mice; R463W FHBL mutant analysis","pmids":["12518019","10769147","12588952","12551903"],"confidence":"High","gaps":["Stoichiometry and dynamics of the ApoB-MTP interaction during assembly not defined","Structural basis of the ionic contacts unresolved"]},{"year":2011,"claim":"Identifying gp78 as the E3 ligase ubiquitinating ApoB upstream of p97 retrotranslocation placed ApoB ERAD within a defined ubiquitin-proteasome circuit and showed its inhibition raises secretion.","evidence":"gp78/p97 single and double siRNA epistasis with ubiquitination assays and lipoprotein fractionation in HepG2","pmids":["21421992"],"confidence":"High","gaps":["Substrate determinants recognized by gp78 unknown","Relationship to luminal pathway unclear"]},{"year":2012,"claim":"Distinguishing Derlin-1 (pre-dislocation) from UBXD8 (post-dislocation, p97 recruitment to lipid droplets) explained how lipidated ApoB reaches the LD surface for proteasomal degradation.","evidence":"Reciprocal siRNA knockdowns, colocalization, ubiquitination and p97 recruitment assays in Huh7","pmids":["22238364"],"confidence":"High","gaps":["Trigger selecting lipidated ApoB for dislocation unknown","Relationship to gp78 pathway not integrated"]},{"year":2012,"claim":"Demonstrating that the ApoB protein particle (not its lipids) downregulates VEGFR1 revealed a non-lipid signaling role for ApoB in negatively regulating angiogenesis.","evidence":"Zebrafish mtp forward genetic screen with ApoB-level rescue and particle-vs-lipid dissection, validated in hyperlipidemic mice","pmids":["22581286"],"confidence":"Medium","gaps":["Molecular receptor/mechanism by which ApoB lowers VEGFR1 unknown","Human relevance not established"]},{"year":2014,"claim":"Solving how LDLR repeat LR5 binds ApoB-100 at two sites with Ca2+/pH-sensitivity provided a structural mechanism for endosomal ligand release independent of beta-propeller displacement.","evidence":"NMR and SPR with synthetic ApoB peptides and LR5 under pH/Ca2+ titration","pmids":["24447298"],"confidence":"High","gaps":["Uses peptides, not intact ApoB on a particle","Full receptor-particle complex geometry not resolved"]},{"year":2020,"claim":"Identifying a TM6SF2-ERLIN1/2-APOB ER complex showed how the NAFLD-associated E167K variant lowers hepatic ApoB and lipid handling by destabilizing TM6SF2.","evidence":"TAP-MS, Co-IP, TM6SF2 luminal-loop domain mapping, and Tm6sf2 knockout/Erlin knockdown mice","pmids":["32776921"],"confidence":"High","gaps":["Degradation pathway engaged when TM6SF2 is lost not defined","How ERLINs stabilize TM6SF2 mechanistically unclear"]},{"year":2022,"claim":"Showing MDM2 directly binds and degrades ApoB independent of p53, and that apo(a) forms noncovalent intracellular complexes with ApoB required for apo(a) secretion, expanded ApoB regulation and connected it to Lp(a) biogenesis.","evidence":"Hepatocyte-specific MDM2 knockout, Co-IP, MDM2-ApoB inhibitor; Co-IP/PLA/colocalization with apo(a) LBS7,8 mutants and APOB siRNA","pmids":["35524581","35045727"],"confidence":"High","gaps":["MDM2 recognition determinants on ApoB unknown","Covalent disulfide maturation of Lp(a) downstream of the noncovalent complex not addressed here"]},{"year":null,"claim":"How the multiple ApoB degradation pathways (cytosolic proteasomal, luminal, LD-associated, gp78-, MDM2-, TM6SF2-dependent) are coordinated and selected for a given particle lipidation state remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unifying model linking lipidation status to degradation route choice","Substrate recognition codes for the distinct E3 ligases undefined","In vivo hierarchy of these pathways in human liver unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0005198","term_label":"structural molecule activity","supporting_discovery_ids":[0,1,21]},{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[1,21,29]},{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[24]},{"term_id":"GO:0140104","term_label":"molecular carrier activity","supporting_discovery_ids":[11,25]}],"localization":[{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[1,2,3,8,22]},{"term_id":"GO:0005811","term_label":"lipid droplet","supporting_discovery_ids":[6]},{"term_id":"GO:0005794","term_label":"Golgi apparatus","supporting_discovery_ids":[22]},{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[11,25]},{"term_id":"GO:0005768","term_label":"endosome","supporting_discovery_ids":[22]}],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[1,2,18]},{"term_id":"R-HSA-382551","term_label":"Transport of small molecules","supporting_discovery_ids":[4,7,24]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[3,6,7,9]},{"term_id":"R-HSA-8953854","term_label":"Metabolism of RNA","supporting_discovery_ids":[10,13,15]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[12,14,23]}],"complexes":["TM6SF2-ERLIN1/2-APOB ER complex","ApoB-MTP complex","Lp(a) (apoB-apo(a) complex)","apoB mRNA editing complex (apobec-1/ACF)"],"partners":["MTTP","TM6SF2","ERLIN1","MDM2","AMFR","LDLR","LPA","LIPC"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P04114","full_name":"Apolipoprotein B-100","aliases":[],"length_aa":4563,"mass_kda":515.5,"function":"Apolipoprotein B is a major protein constituent of chylomicrons (apo B-48), LDL (apo B-100) and VLDL (apo B-100). Apo B-100 functions as a recognition signal for the cellular binding and internalization of LDL particles by the apoB/E receptor","subcellular_location":"Cytoplasm; Secreted; Lipid droplet","url":"https://www.uniprot.org/uniprotkb/P04114/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/APOB","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/APOB","total_profiled":1310},"omim":[{"mim_id":"621417","title":"APOLIPOPROTEIN A-II DEFICIENCY; APOA2D","url":"https://www.omim.org/entry/621417"},{"mim_id":"620410","title":"LOW DENSITY LIPOPROTEIN CHOLESTEROL LEVEL QUANTITATIVE TRAIT LOCUS 3; LDLCQ3","url":"https://www.omim.org/entry/620410"},{"mim_id":"618807","title":"LIPOPROTEIN(a) QUANTITATIVE TRAIT LOCUS; LPAQTL","url":"https://www.omim.org/entry/618807"},{"mim_id":"618666","title":"SITOSTEROLEMIA 2; STSL2","url":"https://www.omim.org/entry/618666"},{"mim_id":"618199","title":"APOBEC1 COMPLEMENTATION FACTOR; A1CF","url":"https://www.omim.org/entry/618199"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Vesicles","reliability":"Supported"},{"location":"Cytosol","reliability":"Supported"}],"tissue_specificity":"Group enriched","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"intestine","ntpm":286.7},{"tissue":"liver","ntpm":1114.1}],"url":"https://www.proteinatlas.org/search/APOB"},"hgnc":{"alias_symbol":["ApoB-100"],"prev_symbol":[]},"alphafold":{"accession":"P04114","domains":[],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P04114","model_url":"","pae_url":"","plddt_mean":null},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=APOB","jax_strain_url":"https://www.jax.org/strain/search?query=APOB"},"sequence":{"accession":"P04114","fasta_url":"https://rest.uniprot.org/uniprotkb/P04114.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P04114/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P04114"}},"corpus_meta":[{"pmid":"12518019","id":"PMC_12518019","title":"Microsomal triglyceride transfer protein and its role in apoB-lipoprotein assembly.","date":"2003","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/12518019","citation_count":466,"is_preprint":false},{"pmid":"202659","id":"PMC_202659","title":"Metabolsim of apoB and apoC lipoproteins in man: kinetic studies in normal and hyperlipoproteininemic subjects.","date":"1978","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/202659","citation_count":218,"is_preprint":false},{"pmid":"3030729","id":"PMC_3030729","title":"The complete sequence and structural analysis of human apolipoprotein B-100: relationship between apoB-100 and apoB-48 forms.","date":"1986","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/3030729","citation_count":213,"is_preprint":false},{"pmid":"15308601","id":"PMC_15308601","title":"Lipid disorders and mutations in the APOB gene.","date":"2004","source":"Clinical chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15308601","citation_count":168,"is_preprint":false},{"pmid":"23913122","id":"PMC_23913122","title":"New therapies targeting apoB metabolism for high-risk patients with inherited dyslipidaemias: what can the clinician expect?","date":"2013","source":"Cardiovascular drugs and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/23913122","citation_count":161,"is_preprint":false},{"pmid":"11352979","id":"PMC_11352979","title":"Secretion of hepatocyte apoB is inhibited by the flavonoids, naringenin and hesperetin, via reduced activity and expression of ACAT2 and MTP.","date":"2001","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/11352979","citation_count":149,"is_preprint":false},{"pmid":"23721961","id":"PMC_23721961","title":"The regulation of ApoB metabolism by insulin.","date":"2013","source":"Trends in endocrinology and metabolism: TEM","url":"https://pubmed.ncbi.nlm.nih.gov/23721961","citation_count":134,"is_preprint":false},{"pmid":"1315773","id":"PMC_1315773","title":"The assembly and secretion of ApoB 100-containing lipoproteins in Hep G2 cells. ApoB 100 is cotranslationally integrated into lipoproteins.","date":"1992","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/1315773","citation_count":130,"is_preprint":false},{"pmid":"11160139","id":"PMC_11160139","title":"LPS-binding protein circulates in association with apoB-containing lipoproteins and enhances endotoxin-LDL/VLDL interaction.","date":"2001","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/11160139","citation_count":124,"is_preprint":false},{"pmid":"29650752","id":"PMC_29650752","title":"Lipid transfer proteins in the assembly of apoB-containing lipoproteins.","date":"2018","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/29650752","citation_count":118,"is_preprint":false},{"pmid":"21567073","id":"PMC_21567073","title":"MMP-2 and MMP-9 are prominent matrix metalloproteinases during atherosclerosis development in the Ldlr(-/-)Apob(100/100) mouse.","date":"2011","source":"International journal of molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/21567073","citation_count":109,"is_preprint":false},{"pmid":"22581286","id":"PMC_22581286","title":"ApoB-containing lipoproteins regulate angiogenesis by modulating expression of VEGF receptor 1.","date":"2012","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/22581286","citation_count":100,"is_preprint":false},{"pmid":"22238364","id":"PMC_22238364","title":"Derlin-1 and UBXD8 are engaged in dislocation and degradation of lipidated ApoB-100 at lipid droplets.","date":"2012","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/22238364","citation_count":95,"is_preprint":false},{"pmid":"17658498","id":"PMC_17658498","title":"Hypercholesterolemia increases myocardial oxidative and nitrosative stress thereby leading to cardiac dysfunction in apoB-100 transgenic mice.","date":"2007","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/17658498","citation_count":90,"is_preprint":false},{"pmid":"12588952","id":"PMC_12588952","title":"Blocking microsomal triglyceride transfer protein interferes with apoB secretion without causing retention or stress in the ER.","date":"2003","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/12588952","citation_count":89,"is_preprint":false},{"pmid":"9111073","id":"PMC_9111073","title":"A two-site model for ApoB degradation in HepG2 cells.","date":"1997","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9111073","citation_count":82,"is_preprint":false},{"pmid":"24416033","id":"PMC_24416033","title":"Atheroprotective Vaccination with MHC-II Restricted Peptides from ApoB-100.","date":"2013","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/24416033","citation_count":75,"is_preprint":false},{"pmid":"12551903","id":"PMC_12551903","title":"A novel nontruncating APOB gene mutation, R463W, causes familial hypobetalipoproteinemia.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12551903","citation_count":72,"is_preprint":false},{"pmid":"14523053","id":"PMC_14523053","title":"Effects of atorvastatin versus fenofibrate on apoB-100 and apoA-I kinetics in mixed hyperlipidemia.","date":"2003","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/14523053","citation_count":72,"is_preprint":false},{"pmid":"22247256","id":"PMC_22247256","title":"Prevalence of ANGPTL3 and APOB gene mutations in subjects with combined hypolipidemia.","date":"2012","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/22247256","citation_count":68,"is_preprint":false},{"pmid":"25575569","id":"PMC_25575569","title":"Mutations in RAD21 disrupt regulation of APOB in patients with chronic intestinal pseudo-obstruction.","date":"2015","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/25575569","citation_count":67,"is_preprint":false},{"pmid":"25961461","id":"PMC_25961461","title":"Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects.","date":"2015","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/25961461","citation_count":66,"is_preprint":false},{"pmid":"7597652","id":"PMC_7597652","title":"Exencephaly and hydrocephaly in mice with targeted modification of the apolipoprotein B (Apob) gene.","date":"1995","source":"Teratology","url":"https://pubmed.ncbi.nlm.nih.gov/7597652","citation_count":65,"is_preprint":false},{"pmid":"24234650","id":"PMC_24234650","title":"Novel functional APOB mutations outside LDL-binding region causing familial hypercholesterolaemia.","date":"2013","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24234650","citation_count":63,"is_preprint":false},{"pmid":"11425493","id":"PMC_11425493","title":"Loss of apoB-100 secondary structure and conformation in hydroperoxide rich, electronegative LDL(-).","date":"2001","source":"Free radical biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/11425493","citation_count":61,"is_preprint":false},{"pmid":"10191293","id":"PMC_10191293","title":"Selective modification of apoB-100 in the oxidation of low density lipoproteins by myeloperoxidase in vitro.","date":"1999","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/10191293","citation_count":61,"is_preprint":false},{"pmid":"24534704","id":"PMC_24534704","title":"Impact of myeloperoxidase-LDL interactions on enzyme activity and subsequent posttranslational oxidative modifications of apoB-100.","date":"2014","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/24534704","citation_count":60,"is_preprint":false},{"pmid":"1597147","id":"PMC_1597147","title":"Effects of growth hormone on apolipoprotein-B (apoB) messenger ribonucleic acid editing, and apoB 48 and apoB 100 synthesis and secretion in the rat liver.","date":"1992","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/1597147","citation_count":57,"is_preprint":false},{"pmid":"28865324","id":"PMC_28865324","title":"The impact of APOA5, APOB, APOC3 and ABCA1 gene polymorphisms on ischemic stroke: Evidence from a meta-analysis.","date":"2017","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/28865324","citation_count":55,"is_preprint":false},{"pmid":"7908536","id":"PMC_7908536","title":"ApoB-100 gene EcoRI polymorphism. Relations to plasma lipoprotein changes associated with abdominal visceral obesity.","date":"1994","source":"Arteriosclerosis and thrombosis : a journal of vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/7908536","citation_count":55,"is_preprint":false},{"pmid":"10769147","id":"PMC_10769147","title":"Decreased secretion of ApoB follows inhibition of ApoB-MTP binding by a novel antagonist.","date":"2000","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10769147","citation_count":53,"is_preprint":false},{"pmid":"12700342","id":"PMC_12700342","title":"PPAR(alpha) and PPAR(gamma) activators suppress the monocyte-macrophage apoB-48 receptor.","date":"2003","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/12700342","citation_count":52,"is_preprint":false},{"pmid":"10559016","id":"PMC_10559016","title":"Decreased production rates of VLDL triglycerides and ApoB-100 in subjects heterozygous for familial hypobetalipoproteinemia.","date":"1999","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/10559016","citation_count":52,"is_preprint":false},{"pmid":"32776921","id":"PMC_32776921","title":"Disruption of the ERLIN-TM6SF2-APOB complex destabilizes APOB and contributes to non-alcoholic fatty liver disease.","date":"2020","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/32776921","citation_count":51,"is_preprint":false},{"pmid":"9165300","id":"PMC_9165300","title":"Oxidative modifications of apoB-100 by exposure of low density lipoproteins to HOCL in vitro.","date":"1997","source":"Free radical biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/9165300","citation_count":50,"is_preprint":false},{"pmid":"30429453","id":"PMC_30429453","title":"Clinical significance of APOB inactivation in hepatocellular carcinoma.","date":"2018","source":"Experimental & molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30429453","citation_count":49,"is_preprint":false},{"pmid":"21293001","id":"PMC_21293001","title":"Human resistin stimulates hepatic overproduction of atherogenic ApoB-containing lipoprotein particles by enhancing ApoB stability and impairing intracellular insulin signaling.","date":"2011","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/21293001","citation_count":45,"is_preprint":false},{"pmid":"27665711","id":"PMC_27665711","title":"The RNA-binding protein vigilin regulates VLDL secretion through modulation of Apob mRNA translation.","date":"2016","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/27665711","citation_count":44,"is_preprint":false},{"pmid":"2143212","id":"PMC_2143212","title":"Solubility, immunochemical, and lipoprotein binding properties of apoB-100-apo[a], the protein moiety of lipoprotein[a].","date":"1990","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/2143212","citation_count":44,"is_preprint":false},{"pmid":"9339363","id":"PMC_9339363","title":"Estimation of the age of the ancestral arginine3500-->glutamine mutation in human apoB-100.","date":"1997","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/9339363","citation_count":43,"is_preprint":false},{"pmid":"35524581","id":"PMC_35524581","title":"Hepatic MDM2 Causes Metabolic Associated Fatty Liver Disease by Blocking Triglyceride-VLDL Secretion via ApoB Degradation.","date":"2022","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/35524581","citation_count":41,"is_preprint":false},{"pmid":"3606734","id":"PMC_3606734","title":"The chromogenicity and quantitation of apoB-100 and apoB-48 of human plasma lipoproteins on analytical SDS gel electrophoresis.","date":"1987","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/3606734","citation_count":39,"is_preprint":false},{"pmid":"21343632","id":"PMC_21343632","title":"Antisense oligonucleotide reduction of apoB-ameliorated atherosclerosis in LDL receptor-deficient mice.","date":"2011","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/21343632","citation_count":39,"is_preprint":false},{"pmid":"23643485","id":"PMC_23643485","title":"Impact of ApoB-100 expression on cognition and brain pathology in wild-type and hAPPsl mice.","date":"2013","source":"Neurobiology of aging","url":"https://pubmed.ncbi.nlm.nih.gov/23643485","citation_count":36,"is_preprint":false},{"pmid":"35536648","id":"PMC_35536648","title":"Immunization using ApoB-100 peptide-linked nanoparticles reduces atherosclerosis.","date":"2022","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/35536648","citation_count":35,"is_preprint":false},{"pmid":"8148348","id":"PMC_8148348","title":"ApoB metabolism in familial hypercholesterolemia. Inconsistencies with the LDL receptor paradigm.","date":"1994","source":"Arteriosclerosis and thrombosis : a journal of vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/8148348","citation_count":35,"is_preprint":false},{"pmid":"15135245","id":"PMC_15135245","title":"A new but frequent mutation of apoB-100-apoB His3543Tyr.","date":"2004","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/15135245","citation_count":35,"is_preprint":false},{"pmid":"15489541","id":"PMC_15489541","title":"LDL phospholipid hydrolysis produces modified electronegative particles with an unfolded apoB-100 protein.","date":"2004","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/15489541","citation_count":35,"is_preprint":false},{"pmid":"21421992","id":"PMC_21421992","title":"Ubiquitination regulates the assembly of VLDL in HepG2 cells and is the committing step of the apoB-100 ERAD pathway.","date":"2011","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/21421992","citation_count":34,"is_preprint":false},{"pmid":"22128163","id":"PMC_22128163","title":"ApoB-100-containing lipoproteins are major carriers of 3-iodothyronamine in circulation.","date":"2011","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22128163","citation_count":33,"is_preprint":false},{"pmid":"33418990","id":"PMC_33418990","title":"The LDLR, APOB, and PCSK9 Variants of Index Patients with Familial Hypercholesterolemia in Russia.","date":"2021","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/33418990","citation_count":32,"is_preprint":false},{"pmid":"9508071","id":"PMC_9508071","title":"Genetic heterogeneity in familial hypobetalipoproteinemia: linkage and non-linkage to the apoB gene in Caucasian families.","date":"1998","source":"American journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/9508071","citation_count":32,"is_preprint":false},{"pmid":"1823939","id":"PMC_1823939","title":"The molecular mechanism for the assembly and secretion of ApoB-100-containing lipoproteins.","date":"1991","source":"Progress in lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/1823939","citation_count":31,"is_preprint":false},{"pmid":"3840371","id":"PMC_3840371","title":"Human ApoB-100 gene resides in the p23----pter region of chromosome 2.","date":"1985","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/3840371","citation_count":31,"is_preprint":false},{"pmid":"2254327","id":"PMC_2254327","title":"Purification and characterization of the nuclear factor BA1. A transcriptional activator of the human apoB gene.","date":"1990","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/2254327","citation_count":31,"is_preprint":false},{"pmid":"33669769","id":"PMC_33669769","title":"ApoB-Specific CD4+ T Cells in Mouse and Human Atherosclerosis.","date":"2021","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/33669769","citation_count":30,"is_preprint":false},{"pmid":"24447298","id":"PMC_24447298","title":"LDL receptor/lipoprotein recognition: endosomal weakening of ApoB and ApoE binding to the convex face of the LR5 repeat.","date":"2014","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/24447298","citation_count":30,"is_preprint":false},{"pmid":"28711866","id":"PMC_28711866","title":"Identification of apoB-100 Peptide-Specific CD8+ T Cells in Atherosclerosis.","date":"2017","source":"Journal of the American Heart Association","url":"https://pubmed.ncbi.nlm.nih.gov/28711866","citation_count":29,"is_preprint":false},{"pmid":"19330716","id":"PMC_19330716","title":"Splicing therapeutics in SMN2 and APOB.","date":"2009","source":"Current opinion in molecular therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/19330716","citation_count":29,"is_preprint":false},{"pmid":"31043469","id":"PMC_31043469","title":"ApoB, small-dense LDL-C, Lp(a), LpPLA2 activity, and cognitive change.","date":"2019","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/31043469","citation_count":29,"is_preprint":false},{"pmid":"20890106","id":"PMC_20890106","title":"apoB and apobec1, two genes key to lipid metabolism, are transcriptionally regulated by p53.","date":"2010","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/20890106","citation_count":29,"is_preprint":false},{"pmid":"2723543","id":"PMC_2723543","title":"Metabolic behavior of hepatic VLDL and plasma LDL apoB-100 in African green monkeys.","date":"1989","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/2723543","citation_count":29,"is_preprint":false},{"pmid":"25677313","id":"PMC_25677313","title":"ApoB-100-related peptide vaccine protects against angiotensin II-induced aortic aneurysm formation and rupture.","date":"2015","source":"Journal of the American College of Cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/25677313","citation_count":28,"is_preprint":false},{"pmid":"18669611","id":"PMC_18669611","title":"Kupffer cell products and interleukin 1beta directly promote VLDL secretion and apoB mRNA up-regulation in rodent hepatocytes.","date":"2008","source":"Innate immunity","url":"https://pubmed.ncbi.nlm.nih.gov/18669611","citation_count":28,"is_preprint":false},{"pmid":"3141543","id":"PMC_3141543","title":"Intracellular apoA-I and apoB distribution in rat intestine is altered by lipid feeding.","date":"1988","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/3141543","citation_count":28,"is_preprint":false},{"pmid":"28874158","id":"PMC_28874158","title":"Associations of the APOB rs693 and rs17240441 polymorphisms with plasma APOB and lipid levels: a meta-analysis.","date":"2017","source":"Lipids in health and disease","url":"https://pubmed.ncbi.nlm.nih.gov/28874158","citation_count":27,"is_preprint":false},{"pmid":"8445339","id":"PMC_8445339","title":"Metabolism of apoB-100-containing lipoproteins in familial hyperchylomicronemia.","date":"1993","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/8445339","citation_count":27,"is_preprint":false},{"pmid":"16920700","id":"PMC_16920700","title":"ApoB mRNA editing is mediated by a coordinated modulation of multiple apoB mRNA editing enzyme components.","date":"2006","source":"American journal of physiology. Gastrointestinal and liver physiology","url":"https://pubmed.ncbi.nlm.nih.gov/16920700","citation_count":27,"is_preprint":false},{"pmid":"10224165","id":"PMC_10224165","title":"Known mutations of apoB account for only a small minority of hypobetalipoproteinemia.","date":"1999","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/10224165","citation_count":27,"is_preprint":false},{"pmid":"23029362","id":"PMC_23029362","title":"Increased tau phosphorylation and impaired presynaptic function in hypertriglyceridemic ApoB-100 transgenic mice.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23029362","citation_count":26,"is_preprint":false},{"pmid":"30076206","id":"PMC_30076206","title":"Directional ABCA1-mediated cholesterol efflux and apoB-lipoprotein secretion in the retinal pigment epithelium.","date":"2018","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/30076206","citation_count":26,"is_preprint":false},{"pmid":"23345063","id":"PMC_23345063","title":"Immune responses elicited by apoB-100-derived peptides in mice.","date":"2013","source":"Immunologic research","url":"https://pubmed.ncbi.nlm.nih.gov/23345063","citation_count":25,"is_preprint":false},{"pmid":"12038793","id":"PMC_12038793","title":"Platelet activation by the apoB/E receptor-binding domain of LDL.","date":"2002","source":"Thrombosis and haemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/12038793","citation_count":25,"is_preprint":false},{"pmid":"29539583","id":"PMC_29539583","title":"Increased Calcific Aortic Valve Disease in response to a diabetogenic, procalcific diet in the LDLr-/-ApoB100/100 mouse model.","date":"2018","source":"Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology","url":"https://pubmed.ncbi.nlm.nih.gov/29539583","citation_count":24,"is_preprint":false},{"pmid":"30270084","id":"PMC_30270084","title":"Further evidence of novel APOB mutations as a cause of familial hypercholesterolaemia.","date":"2018","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/30270084","citation_count":22,"is_preprint":false},{"pmid":"35045727","id":"PMC_35045727","title":"Apo(a) and ApoB Interact Noncovalently Within Hepatocytes: Implications for Regulation of Lp(a) Levels by Modulation of ApoB Secretion.","date":"2022","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/35045727","citation_count":21,"is_preprint":false},{"pmid":"27236033","id":"PMC_27236033","title":"LDLR, ApoB and ApoE genes polymorphisms and classical risk factors in premature coronary artery disease.","date":"2016","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/27236033","citation_count":21,"is_preprint":false},{"pmid":"9555939","id":"PMC_9555939","title":"Secretion of apoB- and apoA-I-containing lipoproteins by chick kidney.","date":"1998","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/9555939","citation_count":20,"is_preprint":false},{"pmid":"24689997","id":"PMC_24689997","title":"The apoB/apoA1 ratio predicts future cardiovascular events in patients with rheumatoid arthritis.","date":"2014","source":"Scandinavian journal of rheumatology","url":"https://pubmed.ncbi.nlm.nih.gov/24689997","citation_count":20,"is_preprint":false},{"pmid":"21722902","id":"PMC_21722902","title":"Mutational analysis of the LDL receptor and APOB genes in Mexican individuals with autosomal dominant hypercholesterolemia.","date":"2011","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/21722902","citation_count":20,"is_preprint":false},{"pmid":"30410436","id":"PMC_30410436","title":"Cerebrovascular Pathology in Hypertriglyceridemic APOB-100 Transgenic Mice.","date":"2018","source":"Frontiers in cellular neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/30410436","citation_count":19,"is_preprint":false},{"pmid":"30553840","id":"PMC_30553840","title":"A serum protein factor mediates maturation and apoB-association of HCV particles in the extracellular milieu.","date":"2018","source":"Journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/30553840","citation_count":19,"is_preprint":false},{"pmid":"8187250","id":"PMC_8187250","title":"Primary structure of apoB-100.","date":"1994","source":"Chemistry and physics of lipids","url":"https://pubmed.ncbi.nlm.nih.gov/8187250","citation_count":19,"is_preprint":false},{"pmid":"22246850","id":"PMC_22246850","title":"The relationship between high-sensitivity C-reactive protein and ApoB, ApoB/ApoA1 ratio in general population of China.","date":"2012","source":"Endocrine","url":"https://pubmed.ncbi.nlm.nih.gov/22246850","citation_count":19,"is_preprint":false},{"pmid":"22074108","id":"PMC_22074108","title":"HBV inhibits apoB production via the suppression of MTP expression.","date":"2011","source":"Lipids in health and disease","url":"https://pubmed.ncbi.nlm.nih.gov/22074108","citation_count":19,"is_preprint":false},{"pmid":"32563005","id":"PMC_32563005","title":"Dietary sucrose induces metabolic inflammation and atherosclerotic cardiovascular diseases more than dietary fat in LDLr-/-ApoB100/100 mice.","date":"2020","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/32563005","citation_count":19,"is_preprint":false},{"pmid":"28902930","id":"PMC_28902930","title":"Association between polymorphisms in the APOB gene and hyperlipidemia in the Chinese Yugur population.","date":"2017","source":"Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas","url":"https://pubmed.ncbi.nlm.nih.gov/28902930","citation_count":18,"is_preprint":false},{"pmid":"20872969","id":"PMC_20872969","title":"ApoB-100, ApoE and CYP7A1 gene polymorphisms in Mexican patients with cholesterol gallstone disease.","date":"2010","source":"World journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/20872969","citation_count":18,"is_preprint":false},{"pmid":"18492086","id":"PMC_18492086","title":"Variable phenotypic expression of homozygous familial hypobetalipoproteinaemia due to novel APOB gene mutations.","date":"2008","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/18492086","citation_count":18,"is_preprint":false},{"pmid":"3034278","id":"PMC_3034278","title":"The human apoB-100 gene: apoB-100 is encoded by a single copy gene in the human genome.","date":"1987","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/3034278","citation_count":18,"is_preprint":false},{"pmid":"9685400","id":"PMC_9685400","title":"Interaction between ApoB and hepatic lipase mediates the uptake of ApoB-containing lipoproteins.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9685400","citation_count":17,"is_preprint":false},{"pmid":"28636837","id":"PMC_28636837","title":"MicroRNA-101-2-5p targets the ApoB gene in the liver of chicken (Gallus Gallus).","date":"2017","source":"Genome","url":"https://pubmed.ncbi.nlm.nih.gov/28636837","citation_count":17,"is_preprint":false},{"pmid":"28457625","id":"PMC_28457625","title":"Effects of atorvastatin and diet interventions on atherosclerotic plaque inflammation and [18F]FDG uptake in Ldlr-/-Apob100/100 mice.","date":"2017","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/28457625","citation_count":17,"is_preprint":false},{"pmid":"12872264","id":"PMC_12872264","title":"Four novel mutations in APOB causing heterozygous and homozygous familial hypobetalipoproteinemia.","date":"2003","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/12872264","citation_count":17,"is_preprint":false},{"pmid":"26345861","id":"PMC_26345861","title":"Relationship of the APOA5/A4/C3/A1 gene cluster and APOB gene polymorphisms with dyslipidemia.","date":"2015","source":"Genetics and molecular research : GMR","url":"https://pubmed.ncbi.nlm.nih.gov/26345861","citation_count":17,"is_preprint":false},{"pmid":"39222019","id":"PMC_39222019","title":"Rare Genetic Variants in LDLR, APOB, and PCSK9 Are Associated With Aortic Stenosis.","date":"2024","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/39222019","citation_count":16,"is_preprint":false},{"pmid":"8172854","id":"PMC_8172854","title":"Cotranslational inhibition of apoB-100 synthesis by cyclosporin A in the human hepatoma cell line HepG2.","date":"1994","source":"Arteriosclerosis and thrombosis : a journal of vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/8172854","citation_count":16,"is_preprint":false},{"pmid":"23637837","id":"PMC_23637837","title":"Roles of ApoB-100 gene polymorphisms and the risks of gallstones and gallbladder cancer: a meta-analysis.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23637837","citation_count":15,"is_preprint":false},{"pmid":"12124991","id":"PMC_12124991","title":"Novel mutations of APOB cause ApoB truncations undetectable in plasma and familial hypobetalipoproteinemia.","date":"2002","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/12124991","citation_count":15,"is_preprint":false},{"pmid":"34590679","id":"PMC_34590679","title":"Meta-GWAS of PCSK9 levels detects two novel loci at APOB and TM6SF2.","date":"2022","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/34590679","citation_count":14,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":57461,"output_tokens":8476,"usd":0.149761,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":18155,"output_tokens":4496,"usd":0.101587,"stage2_stop_reason":"end_turn"},"total_usd":0.251348,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1986,\n      \"finding\": \"ApoB-100 is a single protein of 4560 amino acids (513 kDa) encoded by a single gene; structural analysis predicted amphipathic alpha-helices and beta-sheets as lipid-binding domains, and identified a region (residues 3352-3369) with sequence homology to the LDL receptor-binding site of apoE, flanked by positively charged regions (3174-3681) proposed as the LDL receptor-binding domain.\",\n      \"method\": \"Full-length cDNA sequencing, S1 nuclease mapping of transcription start site, computer secondary structure analysis\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — complete primary structure determination by recombinant DNA methods, replicated across labs and foundational to the field\",\n      \"pmids\": [\"3030729\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"ApoB-100 is cotranslationally integrated into lipoproteins during translocation into the ER lumen; nascent apoB polypeptides are released from ribosomes (via puromycin) and found on lipoprotein particles whose density is inversely related to polypeptide length, establishing that lipoprotein assembly begins co-translationally.\",\n      \"method\": \"Pulse-chase with puromycin/cycloheximide treatment, sucrose gradient ultracentrifugation, electron microscopy, transfection of truncated apoB minigenes, sodium carbonate extraction\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple orthogonal methods (puromycin release, gradient fractionation, EM, minigene transfection) in a single rigorous study\",\n      \"pmids\": [\"1315773\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"MTP binds apoB with high affinity at multiple sites within the N-terminal betaalpha1 structural domain of apoB; this binding is mediated by ionic interactions, is modulated by lipids (lipids on MTP increase binding while lipids on apoB decrease it), and is functionally important for apoB secretion as demonstrated by site-directed mutagenesis, deletion analyses, and a specific antagonist (AGI-S17) that inhibits apoB-MTP binding without affecting MTP lipid transfer activity.\",\n      \"method\": \"Co-immunoprecipitation, site-directed mutagenesis, deletion analysis, antagonist (AGI-S17) inhibition, lipid modulation experiments\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — mutagenesis, reconstituted binding assays, specific antagonist, multiple orthogonal approaches across multiple publications\",\n      \"pmids\": [\"12518019\", \"10769147\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"ApoB-100 undergoes post-translational degradation via two distinct pathways: (1) a cytosolic/proteasome-dependent pathway (ALLN-sensitive) that degrades partially translocated apoB at the cytosolic face of the ER membrane, and (2) an ER luminal pathway (ALLN-resistant, DTT-sensitive) that degrades fully translocated apoB; oleate facilitates translocation of apoB into the lumen, exposing it to the second pathway.\",\n      \"method\": \"Brefeldin A block of ER-to-Golgi transport, ALLN inhibition, DTT reduction, pulse-chase metabolic labeling, inhibitor combination studies in HepG2 cells\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — rigorous pharmacological dissection using multiple specific inhibitors with consistent results, single lab but multiple orthogonal approaches\",\n      \"pmids\": [\"9111073\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Blocking MTP function (by Cre-mediated gene disruption or chemical inhibition) prevents apoB-100 secretion and causes rapid degradation of apoB without its accumulation in ER microsomes; MTP inhibition does not induce ER stress markers (GRP78, GRP94, HSPs), indicating the liver degrades secretion-incompetent apoB rapidly.\",\n      \"method\": \"Cre-mediated MTP gene knockout, chemical MTP inhibitor, plasma lipid measurements, Western blot of apoB in microsomes and chaperones, mouse studies\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — two independent methods (genetic KO and chemical inhibition) with consistent results, in vivo mouse model\",\n      \"pmids\": [\"12588952\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"A naturally occurring nontruncating APOB mutation R463W causes familial hypobetalipoproteinemia by retaining apoB in the ER and reducing secretion efficiency by ~45%; the positive charge at position 463 is critical (Ala substitution reduces secretion; Lys substitution has no effect); the R463W mutant shows increased binding to MTP compared to wild-type, implicating this local domain in apoB-MTP interaction and lipoprotein assembly.\",\n      \"method\": \"Transfection of McA-RH7777 cells with recombinant apoB constructs, pulse-chase analysis, site-directed mutagenesis (Ala, Lys, Glu, Asp substitutions), co-transfection/binding assays with MTP, molecular modeling\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — site-directed mutagenesis with functional secretion assays and MTP binding in a single rigorous study\",\n      \"pmids\": [\"12551903\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"After lipidation in the ER lumen, apoB-100 can be dislocated to the cytoplasmic surface of lipid droplets (LDs) where it accumulates as ubiquitinated ApoB for proteasomal degradation; Derlin-1 mediates the pre-dislocation step (its abrogation causes lipidated apoB to accumulate in ER lumen without increasing ubiquitinated apoB on LDs), while UBXD8 (localized to LDs) mediates the post-dislocation step by recruiting p97 to LDs.\",\n      \"method\": \"siRNA knockdown of UBXD8 and Derlin-1 in Huh7 cells, immunoprecipitation, colocalization studies, ubiquitination assays, p97 recruitment assays\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal knockdowns with distinct phenotypes distinguishing pre- and post-dislocation steps, co-IP for binding, multiple orthogonal methods\",\n      \"pmids\": [\"22238364\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"The E3 ubiquitin ligase gp78 ubiquitinates apoB-100, committing it to p97-mediated retrotranslocation and ERAD; siRNA knockdown of gp78 reduces apoB-100 ubiquitination and cytosolic apoB-ubiquitin conjugates, increases apoB-100 secretion, and unexpectedly enhances VLDL assembly. If p97 is knocked down simultaneously with gp78, cellular apoB returns toward baseline, confirming that ubiquitination precedes p97-mediated retrotranslocation.\",\n      \"method\": \"siRNA knockdown of gp78 and p97 in HepG2 cells, radiolabeling pulse-chase, ubiquitination assays, density gradient fractionation of secreted lipoproteins\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis by double KD, biochemical ubiquitination assay, metabolic labeling in a single rigorous study\",\n      \"pmids\": [\"21421992\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"TM6SF2 forms a complex with ERLIN1/2 and APOB in the ER; TM6SF2 binds and stabilizes APOB via two luminal loops; ERLINs stabilize TM6SF2 (and thereby indirectly stabilize APOB, without directly binding APOB); the NAFLD-associated E167K mutation destabilizes TM6SF2, reducing APOB protein levels; knockout of Tm6sf2 or knockdown of Erlins in mice decreases hepatic APOB protein and causes hepatic lipid accumulation.\",\n      \"method\": \"Tandem affinity purification coupled to mass spectrometry, co-immunoprecipitation, domain mapping (TM6SF2 luminal loop mutants), mouse Tm6sf2 knockout and Erlins knockdown, Western blot for APOB\",\n      \"journal\": \"PLoS genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — TAP-MS for complex identification, Co-IP for validation, domain mutagenesis, in vivo KO/KD with lipid phenotype, multiple orthogonal methods in single study\",\n      \"pmids\": [\"32776921\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"The E3 ubiquitin ligase MDM2 promotes proteasomal degradation of ApoB through direct protein-protein interaction; hepatocyte-specific deletion of MDM2 increases TG-VLDL secretion and protects against diet-induced hepatic steatosis; pharmacological blockage of the MDM2-ApoB interaction alleviates hepatic steatohepatitis and fibrosis; the effect of MDM2 on VLDL metabolism is p53-independent.\",\n      \"method\": \"Hepatocyte-specific MDM2 knockout mice, co-immunoprecipitation, pharmacological MDM2-ApoB interaction inhibitor, pulse-chase/ubiquitination assays, high-fat diet model\",\n      \"journal\": \"Advanced science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO with phenotype, direct protein interaction by Co-IP, pharmacological inhibition, p53-independence shown, multiple orthogonal methods\",\n      \"pmids\": [\"35524581\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"The RNA-binding protein vigilin binds CU-rich regions in the Apob mRNA coding sequence and controls VLDL secretion by modulating ApoB translation; hepatic vigilin knockdown decreases VLDL/LDL levels and atherosclerotic plaque formation in Ldlr-/- mice.\",\n      \"method\": \"Crosslinking-based RNA-binding studies, in vivo vigilin knockdown (siRNA), VLDL/LDL quantification, atherosclerosis scoring in Ldlr-/- mice, genomic approaches\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct RNA-binding crosslinking, in vivo knockdown with lipid and atherosclerosis phenotype, multiple orthogonal methods\",\n      \"pmids\": [\"27665711\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"LPS-binding protein (LBP) circulates in association with LDL and VLDL, and apoB accounts at least in part for LBP's interaction with these lipoproteins; LBP association with LDL/VLDL strongly enhances their capacity to bind LPS, providing a mechanism for lipoprotein-mediated LPS scavenging.\",\n      \"method\": \"Immunoprecipitation/affinity studies with purified LBP and apoB, in vitro LPS binding assays, serum fractionation from healthy persons and septic patients\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — single Co-IP/binding assay identifying apoB as LBP interaction partner, validated in both healthy and septic serum\",\n      \"pmids\": [\"11160139\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"A 60-kDa transcriptional activator protein NF-BA1 binds the apoB promoter region (-79 to -63) and is essential for transcriptional activation of the apoB gene in hepatic and intestinal cells; purified NF-BA1 stimulates apoB transcription in in vitro complementation experiments and also binds regulatory regions of apoCIII, apoAII, and apoAI genes.\",\n      \"method\": \"Protein purification (Q-Sepharose, Bio-Rex 70, DNA affinity chromatography), in vitro transcription complementation, footprinting analysis, photoaffinity cross-linking\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — protein purified to homogeneity, functional in vitro transcription reconstitution, DNA footprinting; single lab but multiple rigorous biochemical methods\",\n      \"pmids\": [\"2254327\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"Growth hormone (GH) regulates apoB mRNA editing in rat liver: hypophysectomy reduces the proportion of edited apoB mRNA (and thus apoB-48) from ~62% to ~29%, while GH replacement restores it to normal levels; GH regulates both editing of apoB mRNA and the proportion of apoB-48 synthesized and secreted.\",\n      \"method\": \"Hypophysectomy with hormone replacement (GH, T4, cortisol) in vivo, S1 nuclease/sequencing for mRNA editing measurement, metabolic labeling of hepatocytes, in vivo labeling experiments\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo genetic/hormonal manipulation with multiple outcome measures, but mechanism downstream of GH not elucidated\",\n      \"pmids\": [\"1597147\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"p53 transcriptionally regulates apoB expression: p53 response elements were identified in the apoB and apobec1 genes; ChIP confirmed p53 binding; in vivo adriamycin (p53 inducer) treatment increased intestinal/liver apoB mRNA; irradiated wild-type but not p53-knockout mice showed elevated hepatic and intestinal apoB mRNA, establishing p53 as a direct transcriptional regulator of apoB.\",\n      \"method\": \"Luciferase reporter assays, chromatin immunoprecipitation (ChIP), RT-PCR in cancer cell lines, adriamycin and irradiation of C57bl/6 and p53-/- mice\",\n      \"journal\": \"Cell cycle\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP confirming direct p53 binding, functional reporter assays, p53-KO genetic control; single lab\",\n      \"pmids\": [\"20890106\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"ApoB mRNA editing is regulated by a coordinated modulation of multiple editing complex components: inhibitory components CUGBP2, GRY-RBP, and hnRNP-C1 suppress editing, while apobec-1 and ACF promote it; siRNA knockdown of CUGBP2, GRY-RBP, or hnRNP-C1 in Caco-2 cells increased editing, confirming their inhibitory function.\",\n      \"method\": \"siRNA knockdown of editing components in Caco-2 cells, quantitative RT-PCR for editing levels and component expression, developmental time-course in mouse fetal intestine\",\n      \"journal\": \"American journal of physiology. Gastrointestinal and liver physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional siRNA knockdown with editing readout, developmental correlation, single lab but multiple editing components tested\",\n      \"pmids\": [\"16920700\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Hepatic lipase (HL) binds directly to apoB (including apoB-26, apoB-48, and apoB-100) but not to apoE or apoA-I, as shown by ligand blot and plate-binding assays; this HL-apoB interaction facilitates cellular uptake of LDL, as HL-enhanced LDL binding and uptake are significantly inhibited by anti-apoB monoclonal antibodies; the interaction differs from LPL in that both amino- and carboxyl-terminal apoB antibodies block HL binding equally.\",\n      \"method\": \"Ligand blot (HL binding to apoB), LDL-coated plate binding assay, 125I-LDL uptake in cell culture, anti-apoB monoclonal antibody inhibition, heparin-agarose binding assay with Kd determination\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct binding assays with purified proteins, functional cell uptake inhibition by antibodies, multiple assay formats\",\n      \"pmids\": [\"9685400\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Human resistin stimulates hepatic ApoB secretion up to 10-fold by increasing MTP activity and by reducing expression/phosphorylation of insulin signaling pathway proteins (IRS-2, Akt, ERK), thereby stabilizing ApoB; resistin also increases hepatocyte lipid content via SREBP1/SREBP2-dependent de novo lipogenesis; antibody immunoprecipitation removal of serum resistin from obese human serum reduces ApoB secretion.\",\n      \"method\": \"Human hepatocyte treatment with resistin, MTP activity assays, Western blot of insulin signaling proteins, SREBP pathway analysis, antibody immunoprecipitation of serum resistin, apoB secretion assays\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple pathway measurements in human hepatocytes, serum depletion experiment as functional validation, single lab\",\n      \"pmids\": [\"21293001\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Naringenin and hesperetin decrease apoB secretion from HepG2 cells by (1) reducing ACAT1 and ACAT2 activities, (2) selectively decreasing ACAT2 mRNA expression, and (3) reducing MTP activity and expression; these effects reduce lipid availability for apoB-containing lipoprotein assembly.\",\n      \"method\": \"HepG2 cell apoB secretion assay, cholesterol esterification assay, ACAT1/ACAT2-transfected CHO cells (isoform selectivity), RT-PCR for ACAT2 mRNA, MTP activity assay, 125I-LDL uptake\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple mechanistic targets investigated with distinct assays, isoform-selective ACAT cells; single lab\",\n      \"pmids\": [\"11352979\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"ApoB negatively regulates angiogenesis by downregulating VEGFR1 (which acts as a decoy receptor for VEGF); genetic screen identified MTP mutation in zebrafish causing vascular defects, which was rescued by manipulating apoB levels; it is the ApoB protein particle (not lipid moieties) that mediates this effect on VEGFR1 and angiogenesis, and VEGFR1 downregulation was also observed in hyperlipidemic mice.\",\n      \"method\": \"Zebrafish forward genetic screen (mtp mutant), zebrafish lipoprotein concentration manipulation, zebrafish and mouse VEGFR1 expression analysis, particle vs. lipid dissection experiments\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic screen plus functional rescue, vertebrate model validation, single lab but multiple species/approaches\",\n      \"pmids\": [\"22581286\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Myeloperoxidase (MPO) selectively oxidizes apoB-100 in LDL via HOCl generation; oxidation with MPO-H2O2-chloride system produces DNPH-reactive carbonyl modifications in specific apoB-100 tryptic peptides (including residues 53-66), with cysteinyl azo and methionine sulfoxide modifications identified; the modifications differ from those produced by reagent HOCl, suggesting direct LDL-MPO interaction at the enzyme active site.\",\n      \"method\": \"In vitro LDL oxidation with MPO, DNPH derivatization, tryptic peptide isolation by HPLC, mass spectrometric peptide characterization\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro biochemical reconstitution with MS-based product identification, selective modification mapping on apoB-100\",\n      \"pmids\": [\"10191293\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"ApoB-100 primary structure analysis identified 16 of 25 cysteine residues in disulfide form (all 14 N-terminal cysteines are disulfide-linked); two free sulfhydryl groups are at positions Cys3734 and Cys4190; trypsin susceptibility defines five structural domains; apoB-100 appears elongated and wraps around the LDL particle, with Cys3734 proposed as the cysteine linked to apo(a) in Lp(a).\",\n      \"method\": \"HPLC-based sulfhydryl/disulfide mapping, fluorescent sulfhydryl probe (iodoacetoamidofluorescein), trypsin domain mapping, protein sequencing combined with recombinant DNA\",\n      \"journal\": \"Chemistry and physics of lipids\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct biochemical characterization of disulfide bonds by HPLC and fluorescent probe; single lab comprehensive structural analysis\",\n      \"pmids\": [\"8187250\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Apo(a) and apoB form noncovalent intracellular complexes within hepatocytes in the ER, trans-Golgi, and early endosomes (not lysosomes); this noncovalent interaction (mediated by apo(a) LBS7,8 sites) is required for apo(a) secretion; PCSK9 enhances apo(a) secretion in an interaction-dependent manner; lomitapide reduces apo(a) secretion dependently on the noncovalent interaction; apoB siRNA knockdown reduces apo(a) secretion.\",\n      \"method\": \"Co-immunoprecipitation, coimmunofluorescence, proximity ligation assay, pulse-chase metabolic labeling, apo(a) LBS7,8 deletion mutant, PCSK9 and lomitapide treatment, siRNA knockdown of APOB\",\n      \"journal\": \"Arteriosclerosis, thrombosis, and vascular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — three independent methods confirming intracellular interaction (Co-IP, colocalization, PLA), functional genetic and pharmacological validation, single lab but highly rigorous\",\n      \"pmids\": [\"35045727\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Mutations in RAD21 that disrupt its transcriptional repressor function cause overexpression of APOB48 in patients with chronic intestinal pseudo-obstruction; wild-type RAD21 protein binds the APOB promoter and represses APOB expression in HEK293 cells, but the p.622 Ala>Thr mutant RAD21 fails to bind the APOB promoter.\",\n      \"method\": \"Mobility shift assay (APOB promoter binding), HEK293 cell transfection with wild-type vs. mutant RAD21, RT-PCR for APOB expression, serum APOB48 measurements in patients\",\n      \"journal\": \"Gastroenterology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct promoter binding assay, functional cell transfection, human patient correlation; single lab\",\n      \"pmids\": [\"25575569\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"The LDLR repeat LR5 binds apoB-100 at two sites (site A and site B) and apoE at its receptor-binding region, at the hydrophilic convex face of LR5; these complexes are weakened at low Ca2+ and low pH, supporting a mechanism where endosomal conditions (low pH, low Ca2+) promote ligand dissociation from LDLR independent of beta-propeller displacement.\",\n      \"method\": \"NMR spectroscopy, surface plasmon resonance (SPR) with synthetic apoB peptides and LR5, pH and Ca2+ titration\",\n      \"journal\": \"The FEBS journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — NMR structure of peptide-LR5 complex with functional SPR validation, mechanistic dissection of pH/Ca2+ effects; single lab but two orthogonal structural/biophysical methods\",\n      \"pmids\": [\"24447298\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"ApoB-100-containing lipoproteins are the major carriers of 3-iodothyronamine (T1AM) in human serum; apoB-100 was identified as the T1AM-binding protein by T1AM-affinity chromatography and sequence analysis; T1AM binds apoB-100-containing LDL particles with Kd ~17 nM and 1:1 stoichiometry; the binding site is highly selective for T1AM; apoB-100-containing particles enhance intracellular T1AM uptake.\",\n      \"method\": \"T1AM-affinity chromatography, protein sequence analysis, competitive binding assays with Kd determination, intracellular uptake assays, in vivo multidose T1AM treatment\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — affinity purification identifies binding partner, quantitative binding characterization, functional uptake assay; single lab\",\n      \"pmids\": [\"22128163\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"ApoB-100 secondary structure (alpha-helical content) is markedly decreased and its conformation is severely altered in electronegative LDL(-), as measured by circular dichroism; tryptophan fluorescence lifetime data indicate that oxidative modification causes apoB-100 to sink into the hydrophobic lipid core of LDL(-), possibly accounting for its reduced LDL receptor binding properties.\",\n      \"method\": \"Circular dichroism spectropolarimetry, tryptophan fluorescence lifetime measurements, Laurdan generalized polarization for lipid packing\",\n      \"journal\": \"Free radical biology & medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct biophysical structural measurements on native and oxidized LDL fractions, two spectroscopic methods; single lab\",\n      \"pmids\": [\"11425493\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"HBV infection inhibits apoB production by suppressing MTP expression; HepG2.2.15 cells (HBV-expressing) show reduced apoB mRNA and protein vs. HepG2; HBV genomic clone transfection dose-dependently reduces MTP mRNA and protein, which in turn reduces apoB expression.\",\n      \"method\": \"RT-PCR and Western blot in HepG2 vs. HepG2.2.15 cells, transfection of HBV infectious clone pHBV1.3, dose-response analysis of MTP suppression\",\n      \"journal\": \"Lipids in health and disease\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, single methods (RT-PCR/Western blot), mechanism is indirect (through MTP), no reconstitution or direct binding data\",\n      \"pmids\": [\"22074108\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1985,\n      \"finding\": \"The human APOB-100 gene was localized to the p23-pter region of chromosome 2 by filter hybridization with apoB-100 cDNA probes and human-mouse somatic cell hybrids containing chromosome 2 translocations.\",\n      \"method\": \"Southern blot hybridization of human-mouse somatic cell hybrids containing chromosome 2 translocations with radiolabeled apoB-100 cDNA probes\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct chromosomal mapping by somatic cell hybrid hybridization; foundational genomic localization\",\n      \"pmids\": [\"3840371\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1990,\n      \"finding\": \"The delipidated apoB-apo(a) complex from Lp(a) is freely water-soluble at pH>6.4 (unlike delipidated apoB alone); apoB-apo(a) has amphipathic properties with apo(a) providing hydrophilic capacity and apoB providing hydrophobic lipid-binding interactions; the complex has avidity for triglyceride-rich lipoprotein particles, demonstrating that apoB's lipid-binding hydrophobic domains are accessible when freed from lipids.\",\n      \"method\": \"Delipidation of Lp(a), solubility assays, sandwich ELISA with apo(a)- and apoB-specific antibodies, interaction with Intralipid emulsion, lipoprotein binding experiments\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — biochemical characterization of delipidated complex by multiple binding and solubility assays; single lab\",\n      \"pmids\": [\"2143212\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ApoB-100 is a 4536-amino acid structural protein that is cotranslationally integrated into nascent lipoprotein particles in the ER lumen, a process dependent on its direct binding to MTP (at the N-terminal betaalpha1 domain, via ionic interactions) and on MTP's lipid transfer activity; poorly lipidated ApoB is degraded via a cytosolic/proteasome pathway (ALLN-sensitive, requiring ERAD machinery including gp78-mediated ubiquitination committing it to p97-mediated retrotranslocation) or an ER luminal pathway (DTT-sensitive), while lipidated ApoB can be dislocated to lipid droplet surfaces for proteasomal degradation via Derlin-1/UBXD8; ApoB stability is further regulated by the TM6SF2-ERLIN complex, by MDM2-mediated ubiquitination, and by vigilin-dependent translational control; ApoB-100 serves as the sole LDL receptor ligand (via its receptor-binding domain around residues 3500) and as a carrier of T1AM and LPS-binding protein; apo(a) forms noncovalent intracellular complexes with ApoB within the ER and Golgi, coupling their secretion; ApoB is transcriptionally regulated by NF-BA1 and p53, and its mRNA editing to generate ApoB-48 is controlled by a multiprotein complex whose activity is modulated by GH and coordinated inhibitory (CUGBP2, GRY-RBP, hnRNP-C1) and activating (apobec-1, ACF) components.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"ApoB-100 is the principal structural protein of atherogenic lipoproteins, serving as a single non-exchangeable scaffold (4536 residues encoded by one gene on chromosome 2) onto which triglyceride- and cholesterol-rich particles are assembled and around which a mature particle is wrapped [#0, #21, #28]. Lipoprotein assembly is co-translational: nascent ApoB is progressively lipidated during translocation into the ER lumen, producing particles whose density falls as polypeptide length increases [#1]. This lipidation requires direct, ionic binding of ApoB's N-terminal betaalpha1 domain to MTP, an interaction modulated by lipid and separable from MTP's lipid-transfer activity; loss of MTP function or local charge mutations such as R463W traps ApoB in the ER and drives its degradation rather than secretion, the latter causing familial hypobetalipoproteinemia [#2, #4, #5]. ApoB that fails to acquire lipid is eliminated through tightly regulated quality-control routes: a cytosolic proteasomal pathway acting on incompletely translocated chains and a DTT-sensitive ER-luminal pathway acting on fully translocated chains [#3], with gp78-mediated ubiquitination committing ApoB to p97-driven retrotranslocation/ERAD, and Derlin-1/UBXD8 routing lipidated ApoB to the lipid-droplet surface for proteasomal degradation [#6, #7]. ApoB stability and output are further set by an ER TM6SF2-ERLIN1/2 complex that binds and stabilizes ApoB, by MDM2-mediated (p53-independent) degradation, and by vigilin-dependent translational control, linking these regulators to VLDL secretion, hepatic steatosis, and atherosclerosis [#8, #9, #10]. Once secreted, ApoB-100 is the sole protein ligand for the LDL receptor, engaging LDLR repeat LR5 at defined sites in a Ca2+/pH-sensitive manner that underlies endosomal ligand release [#24]. ApoB transcription is controlled by NF-BA1 and by p53, and intestinal generation of ApoB-48 arises from C-to-U mRNA editing by an apobec-1/ACF complex antagonized by CUGBP2, GRY-RBP, and hnRNP-C1 and modulated hormonally [#12, #14, #15, #13]. Beyond its structural and receptor roles, ApoB couples apo(a) secretion through noncovalent intracellular complexes [#22] and serves as a carrier protein for circulating ligands.\",\n  \"teleology\": [\n    {\n      \"year\": 1986,\n      \"claim\": \"Establishing that ApoB-100 is a single large protein from one gene with amphipathic lipid-binding helices and an apoE-like LDL-receptor-binding region defined the molecule as the structural scaffold and receptor ligand of LDL.\",\n      \"evidence\": \"Full-length cDNA sequencing and secondary structure prediction, with chromosomal mapping to 2p23-pter by somatic cell hybrids\",\n      \"pmids\": [\"3030729\", \"3840371\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor-binding domain inferred from sequence homology, not direct binding\", \"No experimental tertiary structure\"]\n    },\n    {\n      \"year\": 1992,\n      \"claim\": \"Showing that ApoB is lipidated co-translationally during ER translocation answered whether particle assembly is post-translational, establishing the co-translational assembly model.\",\n      \"evidence\": \"Puromycin/cycloheximide pulse-chase, gradient fractionation, EM, and truncated minigene transfection\",\n      \"pmids\": [\"1315773\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not identify the lipid-transfer machinery responsible\", \"Mechanism coupling length to density not resolved\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Disulfide and domain mapping defined ApoB-100 as an elongated, five-domain protein wrapping the LDL particle and nominated Cys3734 as the apo(a) linkage site, framing its architecture and Lp(a) connection.\",\n      \"evidence\": \"HPLC sulfhydryl/disulfide mapping, fluorescent probe, and trypsin domain mapping\",\n      \"pmids\": [\"8187250\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No high-resolution structure\", \"apo(a) linkage to Cys3734 proposed but not directly demonstrated here\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Resolving ApoB into two degradation routes — cytosolic/proteasomal versus ER-luminal — explained how cells dispose of secretion-incompetent ApoB and linked lipid supply (oleate) to its fate.\",\n      \"evidence\": \"Pharmacological dissection (BFA, ALLN, DTT) with pulse-chase in HepG2 cells\",\n      \"pmids\": [\"9111073\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"E3 ligases and luminal proteases not identified\", \"Single cell line\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Mapping high-affinity ApoB-MTP binding to the betaalpha1 domain via ionic interactions, and showing MTP loss causes rapid ApoB degradation without ER stress, defined MTP as the obligate assembly partner separable from lipid transfer.\",\n      \"evidence\": \"Co-IP, mutagenesis, AGI-S17 antagonist, plus Cre MTP knockout and chemical inhibition in mice; R463W FHBL mutant analysis\",\n      \"pmids\": [\"12518019\", \"10769147\", \"12588952\", \"12551903\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry and dynamics of the ApoB-MTP interaction during assembly not defined\", \"Structural basis of the ionic contacts unresolved\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Identifying gp78 as the E3 ligase ubiquitinating ApoB upstream of p97 retrotranslocation placed ApoB ERAD within a defined ubiquitin-proteasome circuit and showed its inhibition raises secretion.\",\n      \"evidence\": \"gp78/p97 single and double siRNA epistasis with ubiquitination assays and lipoprotein fractionation in HepG2\",\n      \"pmids\": [\"21421992\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Substrate determinants recognized by gp78 unknown\", \"Relationship to luminal pathway unclear\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Distinguishing Derlin-1 (pre-dislocation) from UBXD8 (post-dislocation, p97 recruitment to lipid droplets) explained how lipidated ApoB reaches the LD surface for proteasomal degradation.\",\n      \"evidence\": \"Reciprocal siRNA knockdowns, colocalization, ubiquitination and p97 recruitment assays in Huh7\",\n      \"pmids\": [\"22238364\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Trigger selecting lipidated ApoB for dislocation unknown\", \"Relationship to gp78 pathway not integrated\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Demonstrating that the ApoB protein particle (not its lipids) downregulates VEGFR1 revealed a non-lipid signaling role for ApoB in negatively regulating angiogenesis.\",\n      \"evidence\": \"Zebrafish mtp forward genetic screen with ApoB-level rescue and particle-vs-lipid dissection, validated in hyperlipidemic mice\",\n      \"pmids\": [\"22581286\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular receptor/mechanism by which ApoB lowers VEGFR1 unknown\", \"Human relevance not established\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Solving how LDLR repeat LR5 binds ApoB-100 at two sites with Ca2+/pH-sensitivity provided a structural mechanism for endosomal ligand release independent of beta-propeller displacement.\",\n      \"evidence\": \"NMR and SPR with synthetic ApoB peptides and LR5 under pH/Ca2+ titration\",\n      \"pmids\": [\"24447298\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Uses peptides, not intact ApoB on a particle\", \"Full receptor-particle complex geometry not resolved\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Identifying a TM6SF2-ERLIN1/2-APOB ER complex showed how the NAFLD-associated E167K variant lowers hepatic ApoB and lipid handling by destabilizing TM6SF2.\",\n      \"evidence\": \"TAP-MS, Co-IP, TM6SF2 luminal-loop domain mapping, and Tm6sf2 knockout/Erlin knockdown mice\",\n      \"pmids\": [\"32776921\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Degradation pathway engaged when TM6SF2 is lost not defined\", \"How ERLINs stabilize TM6SF2 mechanistically unclear\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Showing MDM2 directly binds and degrades ApoB independent of p53, and that apo(a) forms noncovalent intracellular complexes with ApoB required for apo(a) secretion, expanded ApoB regulation and connected it to Lp(a) biogenesis.\",\n      \"evidence\": \"Hepatocyte-specific MDM2 knockout, Co-IP, MDM2-ApoB inhibitor; Co-IP/PLA/colocalization with apo(a) LBS7,8 mutants and APOB siRNA\",\n      \"pmids\": [\"35524581\", \"35045727\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"MDM2 recognition determinants on ApoB unknown\", \"Covalent disulfide maturation of Lp(a) downstream of the noncovalent complex not addressed here\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the multiple ApoB degradation pathways (cytosolic proteasomal, luminal, LD-associated, gp78-, MDM2-, TM6SF2-dependent) are coordinated and selected for a given particle lipidation state remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unifying model linking lipidation status to degradation route choice\", \"Substrate recognition codes for the distinct E3 ligases undefined\", \"In vivo hierarchy of these pathways in human liver unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0005198\", \"supporting_discovery_ids\": [0, 1, 21]},\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [1, 21, 29]},\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [24]},\n      {\"term_id\": \"GO:0140104\", \"supporting_discovery_ids\": [11, 25]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [1, 2, 3, 8, 22]},\n      {\"term_id\": \"GO:0005811\", \"supporting_discovery_ids\": [6]},\n      {\"term_id\": \"GO:0005794\", \"supporting_discovery_ids\": [22]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [11, 25]},\n      {\"term_id\": \"GO:0005768\", \"supporting_discovery_ids\": [22]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [1, 2, 18]},\n      {\"term_id\": \"R-HSA-382551\", \"supporting_discovery_ids\": [4, 7, 24]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [3, 6, 7, 9]},\n      {\"term_id\": \"R-HSA-8953854\", \"supporting_discovery_ids\": [10, 13, 15]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [12, 14, 23]}\n    ],\n    \"complexes\": [\n      \"TM6SF2-ERLIN1/2-APOB ER complex\",\n      \"ApoB-MTP complex\",\n      \"Lp(a) (apoB-apo(a) complex)\",\n      \"apoB mRNA editing complex (apobec-1/ACF)\"\n    ],\n    \"partners\": [\n      \"MTTP\",\n      \"TM6SF2\",\n      \"ERLIN1\",\n      \"MDM2\",\n      \"AMFR\",\n      \"LDLR\",\n      \"LPA\",\n      \"LIPC\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```","audit_flag":null,"evaluation":{"pairwise":"tie","faith_supported":8,"faith_total":8,"faith_pct":100.0}}